Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

MIMEDX Announces Launch of CHORIOFIX™

Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products Further Expands Company's Broad Portfolio of Advanced Wound Care (“AWC”) Products

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields

MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company's AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts.

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA 1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the fourth quarter and full year 2025.

MIMEDX Enters into Exclusive Distribution Agreement with Summit Products Group for Multiple Innovative Surgical & Wound Products

Agreement expands offering to include additional sheet, particulate and flowable products Agreement expands offering to include additional sheet, particulate and flowable products